• TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

    Source: Nasdaq GlobeNewswire / 01 Jun 2023 09:15:00   America/New_York

    N/A
Share on,